OwlTail

Cover image of Scott J. Antonia

Scott J. Antonia

8 Podcast Episodes

Latest 6 Nov 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Similar People

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Most Popular

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Clinical Pharmacology CME/CNE/CPE Video

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019

Episode artwork

Scott J. Antonia, MD, PhD - Addressing Unmet Needs in Earlier Stages of NSCLC With Immunotherapy: Cutting-Edge Research, Clinical Applications, and Practical Challenges

PeerView Internal Medicine CME/CNE/CPE Video Podcast

In this activity, experts in the management of patients with non–small cell lung cancer (NSCLC) discuss the new standard of care for stage III locally advanced unresectable NSCLC following the recent approval of checkpoint inhibitor therapy for patients who have not progressed following chemoradiation therapy. In addition, the faculty consider how immunotherapy should be integrated into the management of patients with stage III NSCLC, the practical nuances of use, including timing and duration of therapy, as well as management of overlapping and nonoverlapping adverse effects, and immunotherapy-based rational treatment approaches that are being evaluated in neoadjuvant and adjuvant settings in earlier stages of lung cancer. Upon completion of this activity, participants will be able to: Describe the rationale for use of immunotherapy in earlier stages (I-III) of NSCLC, Evaluate the latest data on efficacy and safety of immunotherapy in stage III NSCLC, and clinical implications of these data, Discuss the key clinical trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with stage III or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, best practice recommendations, and patient needs.

59mins

17 May 2019